Collegium Pharmaceutical (COLL) Stock Forecast & Price Target

Collegium Pharmaceutical is attractive because its cash-generating pain franchise, led by Belbuca and Xtampza ER, appears more durable than the market assumes, with Belbuca patents running through 2032 and management expecting roughly $310-320 million in free cash flow throughout the forecast period. Its ADHD portfolio adds a second growth engine: Jornay PM posted $46.1 million in 2Q26 revenue, while Azstarys is showing early traction after the May 2026 acquisition and could benefit from the company’s expanded 190-person salesforce and 27,000-practitioner reach. Fundamentally, the combination of differentiated products, underappreciated generic-risk timing, and financial flexibility for share repurchases and business development supports a constructive outlook.

Collegium Pharmaceutical is facing a deteriorating earnings profile because its core pain franchise is under pressure from generic competition, pricing erosion, and shrinking opioid scripts, with 2Q26 Nucynta franchise net revenue down 24% YoY to $35.2M and Xtampza ER down 14% YoY to $45.0M. The outlook is further weakened by uncertainty around Belbuca’s market exclusivity and the possibility of generic entry in 2027, while mandatory REMS programs for Xtampza ER, Nucynta, and Belbuca add compliance costs and execution risk. Although Jornay PM and Azstarys offer growth potential, formulary barriers, payer resistance, and reliance on successful integration of acquired assets leave the company exposed if those newer products fail to offset declining pain revenues.